DUALITYBIO-B (09606) surged over 5% during trading, and as of press time, the stock was up 4.68% to HK$308.4, with trading volume reaching HK$104 million.

On the news front, according to the latest report "2025-2030 China Antibody Drug Conjugate (ADC) Industry Research and Market Investment Decision Report" released by China Research and Intelligence, China's ADC market size is expected to exceed 100 billion yuan in the next five years, becoming the world's second-largest ADC market.

DUALITYBIO-B's DB-1419 (B7-H3/PD-L1 bispecific ADC) has demonstrated excellent efficacy in solid tumor clinical trials, marking a technological breakthrough for Chinese companies in the bispecific ADC field. A research report noted that according to Frost & Sullivan, the global ADC market size was approximately $10.4 billion in 2023, and is expected to reach $115.1 billion by 2032.

According to DUALITYBIO-B's announcement, the company expects to submit marketing applications for DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China in 2025. The company's DB-1311 (B7-H3 ADC) has shown potential best-in-class capabilities in prostate cancer, while DB-1310 (HER3 ADC) is expected to catch up from behind. DB-1305 (TROP2 ADC) and combination exploration with bispecific antibodies are leading globally, with autoimmune and bispecific ADCs continuously driving next-generation ADC frontier exploration.